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In a period of 18 months, 2,469 patients with acute myocardial 
infarction treated with a thrombolytic agent were prospectively 
registered in 61 hospitals. Most patients (73%) were treated with 
streptokinase. Intracranial hemorrhage was observed in 24 pa-
tients, corresponding to an incidence rate of 1% (95% confidence 
interval 0.6% to 1.3% ). The median time interval between the 
start of thrombolytic therapy and the first clinical signs of 
intracranial bleeding was 16 h (range 3 to 36). In total, 16 (66%) 
of the 24 patients died as a result of cerebral hematoma. 
To determine clinical predictive factors, a case-control study 
was conducted. For every patient with intracranial hemorrhage, 
two control patients who received thrombolytic therapy because of 
It has now been shown conclusively (1-13) that thrombolytic 
therapy reduces the mortality rate in patients with evolving 
myocardial infarction despite the increased risk of bleeding 
complications associated with this therapy. Overall, the 
severity and frequency of these hemorrhagic complications 
have been recognized to be acceptable and tolerable. Most 
bleeding complications are of minor importance and related 
to invasive vascular procedures. However, in a small num-
ber of patients, intracranial hemorrhage may occur. Re-
ported incidence rates for intracranial hemorrhage in me-
dium size and large trials (2,3,5,7,8,11,13,14) vary from 0% 
to 1.4%. The ability to recognize patients at increased risk 
for bleeding would help to further substantiate the indica-
tions and contraindications for this therapy. Therefore, this 
study was designed to define the incidence of intracranial 
hemorrhage in association with thrombolytic therapy in 
clinical practice and to identify clinical predictive factors. 
Methods 
Incidence. To determine the incidence of intracranial 
hemorrhage in association with thrombolytic therapy, all 
patients with an acute myocardial infarction treated with a 
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acute infarction in the same hospital and in the same period were 
selected. Detailed clinical characteristics of 22 of the 24 patients as 
well as of 7 other patients with documented intracerebral bleeding 
from the European Cooperative Study Group and of 2 patients 
who sustained intracranial hemorrhage outside the registry period 
were compared with 62 control patients. The results of multivari-
ate logistic regression analysis indicate that patients taking an oral 
anticoagulant before admission, patients with a body weight 
<70 kg and those >65 years old are at higher risk for intracranial 
hemorrhage during thrombolytic therapy. 
(JAm CoU Cardio/1992;19:289-94) 
thrombolytic agent were prospectively registered in 61 hos-
pitals in The Netherlands. This registry was begun in Octo-
ber 1988 and was completed after 18 months. Every month, 
each participating center completed a special registry form in 
which the names of patients who received thrombolytic 
therapy were entered and in which those patients sustaining 
intracranial hemorrhage within the 1st 48 h after the start of 
thrombolytic therapy were identified. The recording of isch-
emic or unclassified cerebrovascular accidents was not re-
quired. 
Clinical predictive factors. A case-control study was con-
ducted to define clinical predictive factors for intracranial 
hemorrhage in association with thrombolytic therapy 
(15,16). For every patient with intracranial hemorrhage, two 
control patients who received thrombolytic therapy because 
of an evolving myocardial infarction in the same hospital in 
the same period were selected. The clinical characteristics of 
the patients with intracranial bleeding were compared with 
those of the control group, including age, low body weight 
( <70 kg), use of anticoagulant or antiplatelet drugs, or both, 
before admission, administration of heparin, oral anticoagu-
lant or antiplatelet therapy alone or in combination after 
admission, hypertension on admission (systolic blood pres-
sure > 165 mm Hg diastolic blood pressure >95 mm Hg, or 
both, on at least two occasions before the start of therapy), 
history of hypertension (patient known to have hypertension 
and treated with at least one antihypertensive drug), periph-
eral vascular disease (history of intermittent claudication or 
vascular bruits on physical examination) and current smok-
ing of cigarettes. In addition, demographic data such as age 
0735-1097/92/$5.00 
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Table I. Total Number of Treated Patients With Subdivision 
According to the Administered Thrombolytic Agent and 
Occurrence of Intracranial Hemorrhage 
No. of 
Thrombolytic Agent Patients ICH 
Streptokinase 1,791 16 
Alteplase (rt-PA) 283 2 
Anistreplase (APSAC) 201 3 
Saruplase/urokinase 194 
Total 2,469 24 
% 
0.9 
0.7 
1.5 
1.5 
I* 
*95% confidence interval 0.6% to 1.3%; chi-square test p > 0.05. 
APSAC = anisoylated plasminogen streptokinase activator complex; ICH = 
intracranial hemorrhage; rt-PA = recombinant tissue-type plasminogen acti-
vator. 
and gender were noted as well as localization of the infarct, 
the choice of the thrombolytic agent, the time interval 
between the administration of thrombolytic therapy and the 
first clinical signs of an acute neurologic event, the diagnos-
tic methods to evaluate the neurologic event and the clinical 
course and time interval between the first clinical signs of the 
event and subsequent death. A distinction was made be-
tween cardiac and neurologic death. Cardiac death was 
defined as death due to arrhythmia or heart failure, or both, 
in relation to myocardial infarction. Death due to intracranial 
hemorrhage was defined as the presence of clinical signs of 
loss of brain stem function (wide nonlight-reactive pupils, 
absence of cornea reflex and compensatory ocular move-
ments and ultimately apnea). 
For every case of intracranial hemorrhage and corre-
sponding control cases, a case record form was completed 
by the first author at the participating center. The clinical 
characteristics were obtained from the medical records. In 
addition, reports by the paramedical staff and the results of 
computed tomography of the brain were reviewed. 
Statistical methods. A chi-square test was used to assess 
the occurrence of intracranial hemorrhage in relation to the 
use of the various thrombolytic agents. The clinical charac-
teristics were compared with use of Fisher's exact test. The 
difference in risk was expressed as the odds ratio with the 
corresponding 95% confidence interval. Univariate and mul-
tivariate logistic regression analyses were performed. 
Results 
Incidence. In a period of 18 months, 2,469 consecutive 
patients with acute myocardial infarction were treated with a 
thrombolytic agent in 61 hospitals. Twenty-four patients 
sustained intracranial hemorrhage, corresponding to an in-
cidence rate of 1% (95% confidence interval 0.6% to 1.3%). 
Most patients were treated with streptokinase; however, the 
incidence of intracranial hemorrhage was equally distributed 
among patients receiving the various thrombolytic drugs 
(Table 1). The diagnosis of intracranial hemorrhage was 
confirmed by computed tomography of the brain in 18 
patients and by necropsy in 1 patient. One patient had 
intraocular hemorrhage on fundoscopy and in four patients 
the diagnosis was based on clinical grounds without inde-
pendent verification (Table 2). In all except three patients, 
the first clinical manifestations of acute hemorrhage were 
observed within 24 h after thrombolytic treatment (range 3 to 
36 h, median 16). Sixteen patients (66%) died. All deaths 
among the patients with intracranial hemorrhage were clas-
sified as due to this bleeding complication. Thirteen patients 
died within 24 h after the diagnosis. The time interval 
between the diagnosis of intracranial bleeding and death 
ranged from 0.5 to 92 h (median 7.5). 
Clinical predictive factors. Detailed data from 22 of the 24 
patients were available. To augment the statistical power of 
the case control study, the data from nine other patients with 
documented intracranial hemorrhage (seven patients from 
the European Cooperative Study Group and two patients 
who sustained intracranial hemorrhage in our hospital out-
side the registry period) were added. In all, 31 patients were 
compared with 62 control patients. There was no statistical 
difference between the baseline characteristics of the 31 
patients and the 62 control patients except for age (65 ± 8 in 
the study group vs. 59 ± 8 in the control group; p < 0.02) 
(Table 3). Body weight <70 kg was associated with a 3.4-fold 
higher risk of intracranial hemorrhage in association with 
thrombolytic therapy (Table 4). Among patients treated 
with streptokinase, the dose index (dose/body weight) was 
higher in patients with intracranial hemorrhage (20,000 ± 
1,000 U/kg) than in the control patients (18,000 ± 1,000 Ulkg; 
p < 0.05). Furthermore, age >65 years, hypertension at 
admission, the use of oral anticoagulant drugs before admis-
sion and the presence of diabetes were associated with a 2.3-
to 4.4-fold higher probability of intracranial bleeding, al-
though the confidence intervals crossed unity. The presence 
of peripheral vascular disease and history of hypertension 
did not appear to be associated with an increased risk, 
considering the wide confidence intervals. Because there 
was an equal distribution of the administration of intrave-
nous and oral anticoagulant drugs and the use of antiplatelet 
therapy during the hospital stay between the patients with 
intracranial hemorrhage and the control patients, use of 
these drugs was not identified as a clinical risk factor for 
intracranial hemorrhage. The same was true for smoking. 
Multivariate logistic regression analysis (Table 5) identi-
fied the use of anticoagulant drugs before admission, body 
weight <70 kg and age >65 years as independent clinical 
predictors for intracranial hemorrhage. These characteristics 
were associated with an increased risk of 5.7, 3.7 and 3.3, 
respectively. 
Discussion 
Incidence. Intracranial hemorrhage is the most dreaded 
complication of thrombolytic therapy, although the gain in 
survival in randomized trials exceeds the risk of intracranial 
hemorrhage. Pooled data from randomized comparisons of 
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Table 2. Clinical Signs and Localization of Intracranial Hemorrhage, Diagnostic Methods and Death in 33 Patients 
Pt Age (yr)/ Thrombolytic Heparin Clinical Diagnostic Hematoma Fatal 
No. Gender Agent ASA (IV) Signs Method Site Outcome 
Patients Recruited During Prospective Registry 
58/M SK Restless, coma, right CT/necropsy Right hemisphere Yes 
hemiplegia 
2 68/M (Pro)-uro + Acute headache, right er Left frontoparietal lobe No 
hemiplegia 
75/M SK + + Confused er Right frontoparietal lobe No 
4 58/F SK + + Headache, nausea, vomitus, er Left temporal lobe Yes 
left hemiplegia 
5 64/M SK + Restless, right hemiplegia er Left hemisphere Yes 
6 62/M APSAC Coma, quadriparalysis Clinical Fundo-oculi Yes 
7 62/M APSAC Confused er Left temporal lobe Yes 
8 73/M SK + Right hemiplegia er Left frontoparietal lobe Yes 
9 65/M SK Left hemiplegia er Right frontoparietal lobe Yes 
10 64/M SK + Headache, confused, Necropsy Left occipital lobe Yes 
hemiplegia 
11 85/M SK + + Headache, confused er Brain stem No 
12 60/F SK + + Headache, left hemiplegia er Right frontoparietal lobe No 
13 71/F rt-PA + + Confused, right hemiplegia er Left occipital lobe No 
14 60/M SK + Headache, confused er Right temporal lobe No 
15 70/F (Pro)-uro Restless er Right frontal lobe Yes 
16 55/M SK + + Headache, right hemiplegia er Left occipital lobe Yes 
17 61/M SK + + Coma er Cerebellum Yes 
18 62/F rt-PA + + Confused er Right parietal lobe No 
19 84/M SK + + Loss of consciousness Clinical Yes 
20 50/M SK + Headache, confused, right Clinical Yes 
hemiplegia 
21 64/M SK + + Confused, coma Clinical ? Yes 
22 70/M (Pro)-uro + Acute loss of consciousness Clinical Yes 
23 65/M SK + Headache, paralysis left arm er Nucleus caudatus, No 
right thalamus 
24 74/M APSAC + + Agitation, headache, coma er Right temporal lobe Yes 
Patients Recruited Outside the Prospective Registry 
25 72/M rt-PA + + Confusion, coma er Right frontoparietal lobe Yes 
26 74/M SK + Headache er Left parieto-occipital No 
lobe, subarachnoidal 
and subdural regions 
27 57/M rt-PA + + Hemiparesis er Subdural region No 
28 57/M rt-PA + + Hemianopsia er Occipital lobe No 
29 65/M rt-PA + + Left hemiplegia er Right cortex No 
30 64/M rt-PA + + Diplopia, ataxia er Cerebellum No 
31 67/M rt-PA + + Cerebellar syndrome er Cerebellum and Yes 
frontoparietal lobe 
32 59/M rt-PA + + Confusion, headache er ? No 
33 64/M rt-PA + + Headache er ? Yes 
APSAC = anisoylated plasminogen streptokinase activator complex (30 U over 3 min); ASA =aspirin; CT = computed tomography ofthe brain; F =female; 
IV= intravenously; M= male; (Pro)-uro = (pro)-urokinase (lOO mg over 60 min); Pt =patient; rt-PA = recombinant tissue-type plasminogen activator (100 mg 
over 6 h in all except Patient 13, who received 100 mg over 180 min, and Patient 18, who received duteplase (0.6 MU/kg over 4 h); SK = streptokinase (1.5 MU 
over 60 min in all patients except Patient 8, who received 3 MU); + = given; - = not given. 
various regimens indicate incidence rates of intracranial 0.3%, respectively, for streptokinase and 0.4% for alteplase. 
hemorrhage expressed as the weighted average for each The higher incidence in this registry may be explained by the 
treatment group of 0.02% for placebo, 0.21% for streptoki- fact that, in common clinical practice, the inclusion and 
nase, 0.5% for alteplase and 0.21% for anistreplase (Table 6). exclusion criteria for thrombolytic therapy are less stringent 
The incidence rate of intracranial hemorrhage in the Second than those of prospective thrombolytic studies. Further-
International Study of Infarct Survival (ISIS-2) (5) and in the more, differences in incidence reported in various studies 
International t-PA/SK mortality trial (13) was 0.1% and may be related to the methods of patient selection and data 
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Table 3. Basic Characteristics and Treatment of Patients With 
Intracranial Hemorrhage and Control Patients 
Patients With Control 
Intracranial Hemorrhage Patients 
No. 31 62 
Male 26 (84%) 48 (79%) 
Age (yr) 65 ± 8 59± 8 
Infarct 
Inferior 6 (19%) 11 (18%) 
Inferoposterior 10 (32%) 28 (45%) 
Anterior 10(32%) 17 (27%) 
Anterolateral 5 (16%) 3 (5%) 
Lateral 0 3 (5%) 
Treatment 
Streptokinase 15 (48%) 35 (57%) 
Alteplase 10 (32%) 20 (33%) 
(Pro )-urokinase 3 (10%) 6 (10%) 
Anistreplase 3 (10%) I (2%) 
collection, quaiity control and possibly as a result of the 
differences in thrombolytic agents, dosages and adjunctive 
therapy. 
No difference was made between "primary" intracranial 
hemorrhage and hemorrhagic transformation of an ischemic 
stroke. Embolic cerebrovascular accidents occur in 0.7% to 
0.9% of patients treated with placebo (5,8), 0.5% of patients 
treated with streptokinase (13) and 0.4% to 0. 7% of patients 
treated with alteplase (8,14). Unfortunately, computed to-
mography of the brain is often of no help in making the 
differential diagnosis. Hemorrhagic conversion of cerebral 
infarction has been reported (14) to occur in about 30% of the 
patients with an ischemic cerebrovascular accident in asso-
ciation with acute myocardial infarction and thrombolytic 
therapy. Intracranial hemorrhage in association with throm-
bolytic therapy predominantly occurs within 24 h after 
initiation of treatment, whereas cerebral infarction super-
venes after 48 h after the start of thrombolytic therapy (14). 
These factors illustrate the difficulty in defining the real 
Table 4. Clinical Predictive Factors for Intracranial Hemorrhage 
by Univariate Analysis 
Odds Ratio 95% Cl 
Body weight <70 kg 3.4 1.3-9.0 
History of diabetes 4.4 0.8-25.8 
Anticoagulant drugs before admission 3.7 0.~-16.7 
Hypertension at admission 2.6 0.8-8.2 
Age >65 years 2.3 0.9-6.0 
History of peripheral vascular disease 3.3 0.5-21.1 
History of hypertension 1.2 0.5-3.3 
Smoking 0.9 0.4-2.3 
Heparin therapy during admission 0.8 0.3-2.6 
Antiplatelet therapy during admission 0.7 0.2-1.7 
Oral anticoagulant therapy during 0.6 0.2-1.9 
admission 
Cl = confidence interval. 
Table 5. Clinical Predictive Factors for Intracranial Hemorrhage: 
Results of Multivariate Logistic Regression Analysis 
Anticoagulant therapy before admission 
Body weight <70 kg 
Age >65 years 
Cl = confidence interval. 
Odds Ratio 
5.7 
3.7 
3.3 
95% Cl 
1.1-29.4 
1.4-9.8 
1.2-10.0 
incidence of this bleeding complication associated with 
administration of thrombolytic agents. 
No difference in incidence of intracranial hemorrhage was 
noted among patients receiving the various thrombolytic 
drugs. However, the number of patients who sustained 
intracranial bleeding in our study precludes a definitive 
conclusion (Table 1). In the International t-PA/SK mortality 
trial (13), including > 10,000 patients randomized to either 
alteplase or streptokinase, 43 patients (0.42%) treated with 
alteplase and 30 patients (0.29%) in the streptokinase group 
sustained intracranial bleeding. This corresponds to an ex-
cess risk of 0.13% with alteplase, with a 95% confidence 
interval ranging from -0.04% to 0.29%. Moreover, there 
was an equal number of ischemic strokes in both groups, but 
a higher number of patients with an unclassified stroke in the 
alteplase group, of whom a number patients will have 
sustained cerebral hemorrhage. The preliminary results of 
the Third International Study of Infarct Survival (ISIS-3) 
(32), in which >40,000 patients were randomized to either 
streptokinase, anistreplase or duteplase, the latter being a 
double-chain tissue plasminogen activator (t-PA) with a 
different molecular structure from that of the predominantly 
single-chain alteplase, seems to confirm the higher rate of 
intracranial hemorrhage after recombinant tissue-type plas-
minogen activator (rt-PA) administration. 
Clinical predictive factors. To determine clinical predic-
tive factors for intracranial hemorrhage, a case-control study 
was conducted. Such a study design has been shown to be 
the most efficient and reliable method to study rare events 
(15,16). Multivariate logistic regression analysis identified 
anticoagulant therapy before admission, low body weight 
and age >65 years as independent predictive risk factors for 
intracranial hemorrhage. Oral anticoagulant drugs are 
known to be associated with an increased risk of "sponta-
neous" intracerebral hemorrhage and other bleeding com-
plications (33). Apparently this risk is enhanced in associa-
tion with thrombolytic therapy. 
Intracranial hemorrhage occurred more frequently in 
patients with a low body weight. Because the dose index of 
streptokinase was higher in patients with intracranial hem-
orrhage than in the control patients (p :::; 0.05), this is most 
likely explained by an "overdosing" of the patients who 
sustained intracranial hemorrhage. If these findings are 
confirmed by other trials, the dose of streptokinase should 
be adjusted for body weight. A difference in the dose index 
of recombinant t-PA (rt-PA) was not found in this study. 
However, a dose-related risk of intracranial hemorrhage had 
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Table 6. Frequency of Intracranial Hemorrhage in Association With Thrombolytic Therapy Expressed as Weighted Average of Pooled 
Data From Randomized Trials 
Treatment No. !CH 
Placebo 13,141 2 
Streptokinase 20,652 43 
Alteplase 17,894 88 
Anistreplase 1,940 4 
Abbreviations as in Tables 1 and 4. 
been reported for alteplase and was the reason that the dose 
of alteplase was reduced from 150 to 100 mg/6 h in the 
Thrombolysis in Myocardial Infarction (TIMI) Trial (34). 
Patients >65 years old had a threefold higher probability 
of cerebral hemorrhage. This finding is in agreement with the 
findings of the TIMI-11 Trial (14) and is probably related to 
more common defects in cerebrovascular integrity. Congo-
phylic amyloid angiopathy is prevalent in the elderly (35,36). 
Fibrinolysis may disrupt the naturally occurring microhemo-
stasis in cerebral vessels and thus induce bleeding. More-
over, previous studies (37,38) reported age to be an indepen-
dent risk factor for other bleeding complications after 
thrombolytic therapy. 
Traditional teaching is that chronic high blood pressure is 
a cause of cerebral hemorrhage, but a recent review (33) has 
questioned this hypothesis, our results did not indicate such 
a relation unequivocally; however, hypertension at admis-
sion seemed to be associated with an increased bleeding risk, 
although the relation was not statistically significant (Table 
4). 
Heparin therapy by itself has a low likelihood of causing 
cerebral bleeding. The use of heparin for treatment of 
ischemic stroke is associated with a 0.8% incidence rate of 
hemorrhagic stroke (39). The contribution of heparin therapy 
to the occurrence of intracranial hemorrhage in association 
with thrombolytic therapy is not fully understood (40). In 
this study, heparin was not identified as a risk factor. 
Similarly, antiplatelet therapy with aspirin appeared not to 
be associated with an increased risk for intracerebral bleed-
ing (5). 
Conclusions. Intracranial hemorrhage in association with 
thrombolytic therapy occurs in 1% of the patients. Patients 
using oral anticoagulant drugs before admission and those 
with a low body weight and age >65 years seem to be at 
higher risk. However, the confidence intervals were wide 
and the true impact of these risk factors is not known. It is 
very possible that other or larger studies will reveal addi-
tional risk factors for intracranial hemorrhage. The current 
analysis indicates that thrombolytic therapy should not be 
administered to those patients with an increased risk for 
intracranial hemorrhage in whom a limited benefit of throm-
bolysis may be suspected. This group would include, for 
example, elderly patients who develop a small inferior 
myocardial infarction despite ongoing therapy with antico-
agulant drugs. If more extensive data become available, a 
% 95% Cl Reference 
0.02 0.00-0.06 2,3,5-8,17-23 
0.21 
0.5 
0.21 
0.15-0.27 2,3,5,6,10,11,13,24-28 
0.41-0.59 7 ,8,10,11,13,17-19,24,25,29-31 
0.01-0.41 20-23,26-28 
risk-benefit analysis of therapy would be feasible in each 
patient before initiation of thrombolytic therapy. 
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